GWLL · XBRL financial data
Goldenwell Biotech financial statements, every fiscal year
The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (GWLL's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 16 | 48 | 2 | 0 | 0 |
| Revenue from contracts with customers | 0 | 16 | 48 | 2 | — | — |
| Cost of revenue | 0 | 8 | 23 | 1 | 0 | 0 |
| Gross profit | 0 | 8 | 25 | 1 | 0 | 0 |
| Selling, general and administrative | 6 | 127 | — | — | — | — |
| General and administrative | — | 127 | 1,010 | 118 | 123 | 113 |
| Total operating expenses | 6 | 127 | (1,010) | 118 | 123 | 113 |
| Operating income (loss) | — | (118) | (985) | (117) | (123) | (113) |
| Interest expense | 0 | 0 | — | 2 | 8 | 8 |
| Other income (expense) | 0 | 1 | 0 | — | — | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (6) | (117) | (985) | (117) | (131) | (296) |
| Earnings per share, diluted USD per share | — | — | — | 0.00 | 0.00 | 0.00 |
| Weighted average shares, diluted thousands of shares | — | — | — | 99,000 | 99,000 | 99,000 |
Balance sheet
CSVFiscal years (GWLL's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 249 | 214 | 46 | 53 | 49 | 27 |
| Accounts receivable | — | 0 | 0 | — | — | — |
| Inventory | 0 | 199 | 176 | 175 | 175 | 175 |
| Right-of-use asset | 0 | 49 | 26 | 0 | 0 | 0 |
| Total assets | 249 | 461 | 248 | 228 | 224 | 36 |
| Accounts payable | 0 | 111 | 0 | 0 | 0 | 0 |
| Accrued liabilities | — | — | — | — | 0 | — |
| Total current liabilities | 0 | 159 | — | — | 2 | 102 |
| Long-term debt | — | — | — | 46 | 174 | — |
| Lease liability, non-current | 0 | 0 | — | — | — | — |
| Total liabilities | 0 | 159 | 47 | 143 | 271 | 380 |
| Accumulated deficit | (9) | (126) | (1,111) | (1,228) | (1,360) | (1,656) |
| Total stockholders' equity | 249 | 302 | 202 | 85 | (47) | (344) |
| Total liabilities and equity | 249 | 461 | 248 | 228 | 224 | 36 |
| Common shares outstanding (cover page) thousands of shares | 96,000 | 96,000 | 99,000 | 99,000 | 99,000 | 99,000 |
Cash flows
CSVFiscal years (GWLL's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (6) | (117) | (985) | (117) | (131) | (296) |
| Net cash from operating activities | (6) | (205) | (1,073) | (115) | (123) | (23) |
| Proceeds from issuing common stock | 8 | 92 | 0 | 0 | — | — |
| Proceeds from issuing equity | 0 | 78 | — | — | — | — |
| Proceeds from long-term debt | — | — | 20 | 146 | 119 | — |
| Net cash from financing activities | 8 | 170 | 905 | 122 | 119 | 0 |
Compare with peers
SIC 2000 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Goldenwell Biotech | 11 | 0 | (47)* | 99.0M | 0.2 quarters | 10-QJun 30, 2026 |
| BranchOut Food | 0 | 4,458 | (2,788)* | 15.3M | — | 10-QJun 30, 2026 |
| Borealis Foods | 500 | 7,782 | (123) | 21.5M | 4.1 quarters | 10-QMar 31, 2026 |
| Sow Good | 8.5 | not reported | (2,607)* | 20.1M | 0.0 quarters | 10-QJun 30, 2026 |
| Laird Superfood | 22,969 | 41,294 | 1,451* | 11.2M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.